What the fetus feels.

Abstract

<h3>Objective:</h3> To provide a comprehensive analysis of frequency and spectrum of known genetic risk in ALS patients and assess the clinical utility of performing next-generation sequencing. <h3>Background:</h3> The complex genetic landscape in ALS presents a significant challenge in the clinical setting. Despite the increasing number of pathogenic/risk mutations reported in ALS, the true proportion of cases that can be attributed to genetic factors remains unclear and the actual role of genome-wide screening in clinical practice is still undetermined. <h3>Design/Methods:</h3> Whole-exome sequencing was performed on 950 ALS cases and 675 control samples from an Italian population-based ALS cohort. We screened for coding single-nucleotide variants, indels and expansion in 60 ALS-related genes. Variants were classified by likelihood of pathogenicity according to a pipeline that accounted for minor allele frequency, absence from the control cohort and integrated pathogenicity predictions. Samples were also screened for known repeated expansions. <h3>Results:</h3> We identified 21 pathogenic and likely pathogenic variants, 29 loss of function variants and 180 missense variants classified as deleterious according to our pipeline. These variants were observed in 191 patients (20.1% of our cohort). 71 patients (7.5%) carried the <i>C9ORF72</i> hexanucleotide expansion. Overall, 24.7% of our cohort carried a pathogenic mutation and 3% of cases were found to carry multiple pathogenic variants. Furthermore, we observed the <i>ATXN2</i> intermediate repeat in 36 patients (3.8%). Age at onset (p&lt;0.0252) and family history (p&lt; 0.00001) predicted the likelihood of finding a genetic factor, while gender, site of onset and clinical picture did not. <h3>Conclusions:</h3> We conclusively show that genetic mutations and risk factors in both familial and sporadic ALS patients are more common than previously thought, thus highlighting that genetics play a central role in ALS pathogenesis. Next-generation genetic testing should be offered to all patients diagnosed with ALS for both diagnostic and prognostic purposes. <b>Disclosure:</b> Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Calvo has nothing to disclose. Cristina Moglia has nothing to disclose. Maura Brunetti has nothing to disclose. Ruth Chia has nothing to disclose. Jinhui Ding has nothing to disclose. J. Raphael Gibbs has received research support from NIH. The institution of J. Raphael Gibbs has received research support from Michael J Fox Foundation. J. Raphael Gibbs has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with NIH. Clifton Dalgard has nothing to disclose. Dr. Scholz has received personal compensation for serving as an employee of National Institutes of Health. An immediate family member of Dr. Scholz has received personal compensation for serving as an employee of National Institutes of Health. The institution of Dr. Scholz has received research support from National Institutes of Health. The institution of an immediate family member of Dr. Scholz has received research support from National Institutes of Health. The institution of Dr. Traynor has received research support from ALS Association. The institution of Dr. Traynor has received research support from Merck. The institution of Dr. Traynor has received research support from Myasthenia Gravis Foundation. Dr. Traynor has received intellectual property interests from a discovery or technology relating to health care. Letizia Mazzini has nothing to disclose. Fabiola De Marchi has nothing to disclose. Sandra D9Alfonso has nothing to disclose. Mr. Grassano has nothing to disclose.